Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals (MIRM) will announce late-stage trial results for Livmarli on October 12, aiming to broaden its use in rare liver diseases. The results may impact investor sentiment.
Incyte (INCY) received FDA approval for Atebrioz, a treatment for fibrodysplasia ossificans progressiva. The drug, licensed to Mirum Pharmaceuticals (MIRM), showed a 3.2 cm³ reduction in lesion volume in trials. Incyte also received a Rare Pediatric Disease Priority Review Voucher. Mirum plans U.S. launch in October.
Mirum Pharmaceuticals reported that its Phase 3 AZURE-1 study of brelovitug for chronic hepatitis delta virus met its primary endpoint. The 48-week Phase 2b data showed deepening viral suppression and increased ALT normalization. AZURE-1 is part of the U.S. registration package for brelovitug.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning MIRM (Mirum Pharmaceuticals, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent MIRM coverage spans regulation, financial news and technology.
In the last 30 days, MIRM insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($978K). The most active reporter was BJERKHOLT ERIC, CHIEF FINANCIAL OFFICER, with 1 filing.
The upcoming trial data could move the stock depending on outcome.
Mirum gains a market‑ready product, improving its pipeline and near‑term revenue outlook.
Positive Phase 3 data is likely to lift Mirum's stock as investors price in potential FDA filing and market launch.
Positive Phase III data may lift Mirum's valuation ahead of upcoming BLA filing.
First approved therapy for a rare disease, likely strong upside.
AlphAI scores every news story that mentions MIRM with an AI model for sentiment and relevance, and aggregates insider trades from Mirum Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Mirum Pharmaceuticals (MIRM) will announce late-stage trial results for Livmarli on October 12, aiming to broaden its use in rare liver diseases. The results may impact investor sentiment.
1 min readIncyte (INCY) received FDA approval for Atebrioz, a treatment for fibrodysplasia ossificans progressiva. The drug, licensed to Mirum Pharmaceuticals (MIRM), showed a 3.2 cm³ reduction in lesion volume in trials. Incyte also received a Rare Pediatric Disease Priority Review Voucher. Mirum plans U.S. launch in October.
2 min readMirum Pharmaceuticals reported that its Phase 3 AZURE-1 study of brelovitug for chronic hepatitis delta virus met its primary endpoint. The 48-week Phase 2b data showed deepening viral suppression and increased ALT normalization. AZURE-1 is part of the U.S. registration package for brelovitug.
1 min readMirum Pharmaceuticals (MIRM) announced positive Phase III results for brelovitug in hepatitis delta treatment, with 25% of patients achieving viral suppression. The company plans to submit a biologics license application in early 2025 and expects peak sales of at least $1 billion. Additionally, Mirum received FDA approval for Atebrioz, its fourth commercial medicine, targeting heterotopic ossification in FOP patients.
2 min readEdwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.
3 min readMirum Pharmaceuticals' brelovitug met primary goals in a Phase 3 trial for hepatitis D. The company plans FDA approval filing in early 2027. Currently, only one drug, Gilead's Hepcludex, is approved in the U.S. for certain patients.
3 min readMirum Pharmaceuticals received FDA approval for Atebrioz (zilurgisertib) to treat fibrodysplasia ossificans progressiva (FOP), a rare bone disease. The drug, a once-daily pill, showed significant reduction in new lesion volume in clinical trials. Mirum joins Regeneron and Ipsen in offering treatments for FOP, with Atebrioz being the third approved option in recent months. The company plans to launch the drug in October, with pricing details to be announced.
2 min readMirum Pharmaceuticals (MIRM) reported that brelovitug met primary endpoints in the Phase 3 AZURE-1 study for chronic hepatitis delta. The trial showed virologic response and ALT normalization at 24 weeks. The company plans to submit a BLA in 2027. MIRM stock is down 1.47% to $88.39.
2 min readMirum Pharmaceuticals' phase 3 trial of brelovitug for chronic hepatitis delta met its primary endpoint, with response rates of 56% and 45% for the 300 mg and 900 mg doses, respectively. The results surpassed the delayed treatment arm and showed improvement over phase 2b data. Analysts note potential commercial differentiation. Mirum aims for FDA approval by mid-2025, following positive Azure-4 trial data expected in Q4 2024.
2 min readMirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Approval of Atebrioz On September 25, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) and Incyte Corporation (“Incyte”) announced that the U.S. Food and Drug Administration (“FDA”) approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total
2 min read
